LifeSci Advisors, LLC’s Post

🧐Check out the #Article "Exploring Connections between Oral Microbiota, Short-Chain Fatty Acids, and Specific Cancer Types: A Study of Oral Cancer, Head and Neck Cancer, Pancreatic Cancer, and Gastric Cancer" 👏by Zahra Nouri et al. Access the full paper here👉 https://lnkd.in/dk2xpG6g Keywords: oral microbiota; machine learning; SCFAs;

In our newest Pharmacy Times Insights Series, titled "Advancing Treatment of EGFR-Positive Metastatic Non-Small Cell Lung Cancer", Cara Chang explores the prevalence of EGFR mutations in NSCLC and takes a dive into the different therapeutic options for patients. Navigate to the link below to watch the full episode on pharmacytimes.com: https://lnkd.in/dGdsVhMu

Today we presented positive overall survival data from the phase 2 trial of CAN-2409 in non-small cell lung cancer in a poster presentation at #ASCO2024.   The poster highlights treatment with CAN-2409 resulted in a median overall survival of 20.6 months compared to published results of median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient population, activation of a systemic immune response and a favorable safety profile.   View the full poster here: https://bit.ly/45bwIow

#sponsored Do you have hormone receptor-positive, early-stage breast cancer and wonder what your risk of recurrence is? Genomic tests can help provide personalized information to assess your risk, and how length of treatment may or may not reduce that risk. The Breast Cancer Index® test provides an estimate of your individual risk of distant recurrence between years 5 and 10, and whether longer anti-estrogen therapy is likely to help. Knowing your personalized risk and what you can do about it can help reduce anxiety as a breast cancer survivor. #breastcancerindex #findyourfinish @Hologic @breastcancerorg #breastcancersurvivor

#OnTheBlog: We summarize the five fast facts of what we uncovered in our recent analysis with Renown Health and the Healthy Nevada Project® that emphasizes the importance of genetic approaches to breast cancer screenings. The study revealed that a combined monogenic and polygenic approach to screenings offers more accurate insights into a patient's likelihood of developing breast cancer in the future. This tailored approach not only elevates patient well-being but also improves efficiency and equity in healthcare. Read more here: https://bit.ly/3W2fjf8

WEBINAR ALERT! 👉Join Dr. Tyler F. Stewart, a genitourinary malignancies expert from UC San Diego, as he walks you through the journey of treating muscle invasive and advanced bladder cancer. From traditional chemotherapy to today's immunotherapy, discover the progress since BCAN began in 2005. Learn about personalized therapies, Antibody Drug Conjugates, and groundbreaking first-line combinations reshaping bladder cancer care. Understand the evolving landscape of bladder preservation. Click here to register: https://lnkd.in/gKtHvC3e

Fast-track your immunotherapy evaluation. Our syngeneic models are well-characterized, making them the ideal models to evaluate your novel immuno-oncology agents as well as combination therapies. We provide a large collection of syngeneic models covering a variety of cancer types and immune phenotypes, available now for your efficacy and PD studies. Learn more ➡️https://bit.ly/4bHwKr2 #Syngeneic #InVivo #DrugDevelopment

#HighlyAccessedPaper Read now ➡️ "PHI-1, an Endogenous Inhibitor Protein for Protein Phosphatase-1 and a Pan-Cancer Marker, Regulates Raf-1 Proteostasis" by Masumi Eto, et al. This article reveals how PHI-1, a newly recognized pan-cancer marker, regulates Raf-1 proteostasis, enhancing cell growth and reducing apoptosis, with significant implications for cancer therapy. 👉 https://brnw.ch/21wLe3N

Today is #WorldCancerResearchDay, highlighting the critical importance of advancing studies and trials aimed at understanding the disease and developing effective treatments. Today of all days, we are sharing our latest case study, conducted in partnership with a top-10 pharma company on non-small cell lung cancer (NSCLC). The study focuses on metastatic non-small cell lung cancer (NSCLC) in patients with wild-type (WT) tumor profiles, examining diagnosis-to-treatment timelines and the correlation between smoking and disease development. Learn how this research contributes to better data-driven decisions and improved patient outcomes: https://lnkd.in/dmHtpnWt

We've just published our study that could revolutionize treatment options for unresectable appendiceal adenocarcinoma (AA). A first of its kind, our phase 2 study examines the efficacy and safety of combining atezolizumab with bevacizumab (Atezo+Bev) in battling advanced AA. With limited options available, our research offers a beacon of hope where previously there was little. This pioneering study leverages the synergy of VEGF and PD-1 inhibition—a strategy that’s shown promise in other tumor types—to potentially pioneer a new path for AA treatments. It's a stride forward in precision medicine, offering a personalized and targeted approach for a disease that has long been an orphan in the cancer treatment landscape. To read more about the outcomes: https://lnkd.in/dEY4tuAH #Oncology #ClinicalResearch #MedicalInnovation #CancerCare #Atezolizumab #Bevacizumab